Circassia awarded Pulmonary Function and Metabolic Analyzers agreement with Premier

Posted Jul 15, 2019

July 10, 2019 – (MORRISVILLE, NC) – Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that it has been awarded a group purchasing agreement for Pulmonary Function and Metabolic Analyzers with Premier. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for NIOX® asthma diagnosis and management devices.


“One of Circassia’s primary goals is improving access to NIOX for the millions of Americans who suffer from asthma, and therefore it is extremely gratifying to be awarded this prestigious agreement with Premier,” said David Acheson, SVP US Commercial, Circassia. “This new contract will provide Circassia with a straightforward route to serve Premier members as potential new customers, helping us expand our accounts while offering savings opportunities for NIOX users.”


Circassia’s NIOX products are used to assist asthma diagnosis and management, and are indicated in the United States for use in those aged 7 years and older. NIOX is based on the discovery that patients with allergic/eosinophilic (Th2 or type 2) driven airway inflammation, the major underlying cause of asthma, generally have higher than normal levels of nitric oxide in their exhaled breath. By measuring the concentration of this fractional exhaled nitric oxide (FeNO), NIOX enables clinicians to evaluate airway inflammation in patients with underlying asthma, aiding diagnosis and helping guide treatment and reduce exacerbations.


“This important Premier contract brings Circassia one step closer to expanding respiratory care options for the estimated 25 million Americans who have been diagnosed with asthma,” said Suzanne Monahan, Vice President, NIOX Business Unit. “We look forward to bringing our award-winning contracting/hospital, in-house customer service, and sales teams to this collaborative effort.”


Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and 165,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.


About Circassia Pharmaceuticals Inc.
Circassia Pharmaceuticals Inc. is part of the Circassia Pharmaceuticals plc group. Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom, China and Germany, and in a wide range of other countries through its network of partners. In the United States, Circassia has a commercial collaboration with AstraZeneca in which it has the commercial rights to chronic obstructive pulmonary disease (COPD) treatments TUDORZA® PRESSAIR® and DUAKLIR® PRESSAIR®. Circassia also has the commercial rights to the late-state ventilator-compatible nitric oxide product AirNOvent in the United States and China. For more information please visit, or follow us on Twitter @CircassiaUSA and LinkedIn CircassiaUSA.


# # #